ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (AB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02858076
Recruitment Status : Recruiting
First Posted : August 8, 2016
Last Update Posted : October 2, 2017
Sponsor:
Collaborators:
National Institutes of Health (NIH)
Regeneron Pharmaceuticals
National Eye Institute (NEI)
Information provided by (Responsible Party):
Jaeb Center for Health Research

Brief Summary:
Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment method is most likely to provide the best visual outcomes once intervention is desired. Intravitreous anti-vascular endothelial growth factor (anti-VEGF) therapy alone or vitrectomy combined with intraoperative PRP each provide the opportunity to stabilize or regress retinal neovascularization. However, clinical trials are lacking to elucidate the relative time frame of visual recovery or final visual outcome in prompt vitrectomy compared with initial anti-VEGF treatment. The Diabetic Retinopathy Clinical Research Network Protocol N demonstrated short-term trends consistent with a possible beneficial effect of anti-VEGF treatment in eyes with VH from PDR, including greater visual acuity improvement and reduced rates of recurrent VH as compared with saline injection. It is possible that a study with a longer duration of follow-up with structured anti-VEGF retreatment would demonstrate even greater effectiveness of anti-VEGF for VH to avoid vitrectomy and its attendant adverse events while also improving visual acuity. On the other hand, advances in surgical techniques leading to faster operative times, quicker patient recovery, and reduced complication rates may make prompt vitrectomy a more attractive alternative since it results in the immediate ability to clear hemorrhage and to perform PRP if desired, often as part of one procedure. This proposed study will evaluate the safety and efficacy of two treatment approaches for eyes with VH from PDR: prompt vitrectomy + PRP and intravitreous aflibercept injections.

Condition or disease Intervention/treatment Phase
Proliferative Diabetic Retinopathy Vitreous Hemorrhage Drug: 2-mg Intravitreous Aflibercept Injection Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
Study Start Date : November 2016
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Intravitreous 2 mg aflibercept injections
Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
Drug: 2-mg Intravitreous Aflibercept Injection
Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
Other Names:
  • Eylea
  • Vascular endothelial growth factor Trap-Eye

Active Comparator: Prompt vitrectomy plus panretinal photocoagulation
For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation
Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
Other Name: PRP




Primary Outcome Measures :
  1. Visual Acuity Area Under the Curve [ Time Frame: Between randomization and 24 weeks ]

Secondary Outcome Measures :
  1. Visual Acuity Area Under the Curve [ Time Frame: Between randomization and 52 weeks ]
  2. Visual Acuity Area Under the Curve [ Time Frame: Between randomization and 104 weeks ]
  3. Mean Visual Acuity [ Time Frame: 4 Weeks ]
  4. Mean Visual Acuity [ Time Frame: 12 Weeks ]
  5. Mean Visual Acuity [ Time Frame: 24 Weeks ]
  6. Mean Visual Acuity [ Time Frame: 1-Year from participant randomization ]
  7. Mean Visual Acuity [ Time Frame: 2-Years from participant randomization ]
  8. Percent 20/20 or better, 20/32 or better, 20/40 or better, 20/200 or worse, and 20/800 or worse [ Time Frame: 4 weeks ]
  9. Percent 20/20 or better, 20/32 or better, 20/40 or better, 20/200 or worse, and 20/800 or worse [ Time Frame: 12 weeks ]
  10. Percent 20/20 or better, 20/32 or better, 20/40 or better, 20/200 or worse, and 20/800 or worse [ Time Frame: 24 weeks ]
  11. Percent 20/20 or better, 20/32 or better, 20/40 or better, 20/200 or worse, and 20/800 or worse [ Time Frame: 1-Year from participant randomization ]
  12. Percent 20/20 or better, 20/32 or better, 20/40 or better, 20/200 or worse, and 20/800 or worse [ Time Frame: 2-Years from participant randomization ]
  13. Proportion of eyes with at least 15 and at least 30 E-ETDRS letter score gains or losses from baseline [ Time Frame: 24 weeks ]
  14. Proportion of eyes with at least 15 and at least 30 E-ETDRS letter score gains or losses from baseline [ Time Frame: 52 weeks ]
  15. Proportion of eyes with at least 15 and at least 30 E-ETDRS letter score gains or losses from baseline [ Time Frame: 104 weeks ]
  16. Rates of recurrent vitreous hemorrhage on clinical exam [ Time Frame: 24 weeks ]
  17. Rates of recurrent vitreous hemorrhage on clinical exam [ Time Frame: 52 weeks ]
  18. Rates of recurrent vitreous hemorrhage on clinical exam [ Time Frame: 104 weeks ]
  19. Percentage of eyes with retinal neovascularization [ Time Frame: 24 weeks ]
  20. Percentage of eyes with retinal neovascularization [ Time Frame: 52 weeks ]
  21. Percentage of eyes with retinal neovascularization [ Time Frame: 104 weeks ]
  22. Mean optical coherence tomography central subfield thickness [ Time Frame: 24 weeks ]
  23. Mean optical coherence tomography central subfield thickness [ Time Frame: 52 weeks ]
  24. Mean optical coherence tomography central subfield thickness [ Time Frame: 104 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >= 18 years Participants <18 years old are not being included because proliferative diabetic retinopathy is so rare in this age group that the diagnosis may be questionable.
  2. Diagnosis of diabetes mellitus (type 1 or type 2)

Any one of the following will be considered to be sufficient evidence that diabetes is present:

  • Current regular use of insulin for the treatment of diabetes
  • Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
  • Documented diabetes by American Diabetes Association and/or World Health Organization criteria 4. Able and willing to provide informed consent. 5. Patient is willing and able to undergo vitrectomy within next 2 weeks and the vitrectomy can be scheduled within that time frame.

    6. Vitreous hemorrhage causing vision impairment, presumed to be from proliferative diabetic retinopathy, for which intervention is deemed necessary.

    • Note: Prior panretinal photocoagulation is neither a requirement nor an exclusion.
    • Subhyaloid hemorrhage alone does not make an eye eligible; however, presence of subhyaloid hemorrhage in addition to the criteria above will not preclude participation provided the investigator is comfortable with either treatment regimen.

      7. Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 months to see if hemorrhage clears sufficiently with anti-vascular endothelial growth factor without having to proceed to vitrectomy).

      8. Visual acuity letter score ≤78 (approximate Snellen equivalent 20/32) and at least light perception.

      9. Investigators should use particular caution when considering enrollment of an eye with visual acuity letter score 69 to 78 (approximate Snellen equivalent 20/32 to 20/40) to ensure that the need for vitrectomy and its potential benefits outweigh the potential risks.

Exclusion Criteria:

  • A potential participant is not eligible if any of the following exclusion criteria are present:

    1. History of chronic renal failure requiring dialysis (including placement of fistula if performed in preparation for dialysis) or kidney transplant.
    2. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
    3. Initiation of intensive insulin treatment (a pump or multiple daily injections) within 4 months prior to randomization or plans to do so in the next 4 months.
    4. A condition that, in the opinion of the investigator, would preclude participant undergoing elective vitrectomy surgery if indicated during the study.
    5. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.

      • Note: participants cannot receive another investigational drug while participating in the study.

    6. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine).
    7. Blood pressure > 180/110 (systolic above 180 or diastolic above 110).
    8. If blood pressure is brought below 180/110 by anti-hypertensive treatment, potential participant can become eligible.
    9. Systemic anti-vascular endothelial growth factor or pro-vascular endothelial growth factor treatment within 4 months prior to randomization.

      • These drugs cannot be used during the study.

    10. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next two years.

      • Women who are potential participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

    11. Potential participant is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the two years.
    12. Evidence of traction detachment involving or threatening the macula.

      • If the density of the hemorrhage precludes a visual assessment on clinical exam to confirm eligibility, then it is recommended that assessment be performed with ultrasound as standard care.

    13. Evidence of rhegmatogenous retinal detachment.

      • If the density of the hemorrhage precludes a visual assessment on clinical exam to confirm eligibility, then it is recommended that assessment be performed with ultrasound as standard care.

    14. Evidence of neovascular glaucoma (iris or angle neovascularization is not an exclusion).
    15. Known diabetic macular edema (DME), defined as either
    16. Optical coherence tomography central subfield thickness (microns):
    17. Zeiss Cirrus: ≥290 in women; ≥305 in men
    18. Heidelberg Spectralis: ≥305 in women; ≥320 in men OR
    19. Diabetic macular edema on clinical exam that the investigator believes currently requires treatment.
    20. History of intravitreous anti-vascular endothelial growth factor treatment within 2 months prior to current vitreous hemorrhage onset or after onset.
    21. History of intraocular corticosteroid treatment within 4 months prior to current vitreous hemorrhage onset or after onset.
    22. History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or major ocular surgery other than vitrectomy anticipated within the next 6 months following randomization.
    23. History of vitrectomy.
    24. History of YAG capsulotomy performed within 2 months prior to randomization.
    25. Aphakia.
    26. Uncontrolled glaucoma (in investigator's judgment).
    27. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02858076


Contacts
Contact: Adam Glassman, MS 813-975-8690 drcrnet@jaeb.org

  Show 62 Study Locations
Sponsors and Collaborators
Jaeb Center for Health Research
National Institutes of Health (NIH)
Regeneron Pharmaceuticals
National Eye Institute (NEI)
Investigators
Study Chair: Andrew Antoszyk, MD Charlotte Eye, Ear, Nose and Throat Assoc., PA

Responsible Party: Jaeb Center for Health Research
ClinicalTrials.gov Identifier: NCT02858076     History of Changes
Other Study ID Numbers: DRCR.net Protocol AB
EY14231 ( Other Grant/Funding Number: National Eye Institute )
EY23207 ( Other Grant/Funding Number: National Eye Institute )
EY18817 ( Other Grant/Funding Number: National Eye Institute )
First Posted: August 8, 2016    Key Record Dates
Last Update Posted: October 2, 2017
Last Verified: September 2017

Keywords provided by Jaeb Center for Health Research:
Anti-VEGF
Vitrectomy

Additional relevant MeSH terms:
Hemorrhage
Retinal Diseases
Diabetic Retinopathy
Vitreous Hemorrhage
Pathologic Processes
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Eye Hemorrhage
Mitogens
Bevacizumab
Endothelial Growth Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents